SUMMARY Highly purified recombinant human renin (rh-renin), synthesized by Chinese hamster ovary cells, was labeled with todine-125 and was given Intravenously to pentobarbital-anestbetized common marmosets (Callithrix jacchus) to study the fate of the circulating renin. Specific anti-rh-renin antiserum was used to identify the ^-rh-renin. Plasma disappearance of the exogenously administered '"I-rh-renin In marmosets (n = 6) showed two exponential components, with a half-life of 12.1 ± 1.9 minutes for the rapid component and 120. T HE plasma level of renin, a key enzyme of the renin-angiotensin system, 1 is regulated by the rate of release from the kidney and by plasma clearance. We studied the plasma clearance of exogenously administered mouse submaxillary renin in mice and rat renal renin in rats, both labeled with iodine-125 and found that mouse submaxillary renin is cleared mainly by the kidney, 2 -5 while rat renal renin is cleared by the liver as well as by the kidney. 6 -9 We suggested the possible contribution of glycosylation of renal renin to the hepatic distribution. 6 -9 However, there is a significant difference in the characteristics of the renin-angiotensin system between human renin and laboratory animal renins, including dog, hog, rat, and mouse renin.
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Preparation of Recombinant Human Renin
rh-Renin, expressed in Chinese hamster ovary cells transfected with a plasmid containing the human renin cDNA 16 and activated with trypsin for 2 hours at 24 °C, was purified to apparent homogeneity, as described by Poorman et al. 14 and Murakami et al. 13 rh-Renin is similar to native human renal renin 17 with regard to physiochemical characteristics.
Pressor Activity of Recombinant Human Renin
Experiments were performed on pentobarbitalanesthetized cynomolgus monkeys (25 mg/kg i.v.). A femoral artery was catheterized with a polyvinyl tube for the measurement of blood pressure and heart rate and for the collection of blood samples. A femoral vein was cannulated for the injection of substances. At specified times after the injection of rh-renin, arterial blood (3-5 ml) was collected for the measurement of angiotensins I and II.
Measurement of Plasma Angiotensins I and II
The levels of plasma angiotensins were routinely determined by the method of Kawamura et al. 18 Arterial blood collected from cynomolgus monkeys into a chilled tube containing Na 2 -EDTA powder was immediately centrifuged at 3000 rpm for 15 minutes at 4 °C. Then, 2 ml of plasma was applied to Sep-Pak cartridges (Waters Associates, Milford, MA, USA), and the bound angiotensins were eluted with 3 ml of methanol/water/trifluoroacetic acid (80: 19.9:0.1, vol/vol/vol). The eluates were then applied to a reverse-phase column (TSK gel ODS-80TM, 4.6 x 150 mm; Toyo Soda, Yamaguchi, Japan) and eluted with a 15-minute linear gradient of 10 to 50% methanol at a flow rate of 0.8 ml/min to separate angiotensins I, II, and III. The retention time of angiotensin I, II, and III standards was 27.3, 24.4, and 23.6 minutes, respectively. Radioimmunoassay (RIA) for angtiotensin II was performed using specific antiserum against angiotensin II, a gift from Dr. K. Shimamoto. 19 Sensitivity of the assay was 0.2 pg of angiotensin II. RIA for angiotensin I was performed using specific antiserum against angiotensin I, as reported. I-labeled rh-renin, eluted in the void volume from this column, was then applied to a concanavalin A-Sepharose column (7 x 20 mm) equilibrated with 20 mM phosphate buffer (pH 7.4) containing 0.15 M NaCl at room temperature. The column was exhaustively washed with the equilibration buffer and then eluted with 50 mM a-methyl-D-mannoside in the equilibration buffer, with 0.5-ml fractions being collected. This l23 I-rh-renin was further purified by gel permeation high performance liquid chromatography (HPLC) on a G 3000 SW column (Toyo Soda) equilibrated with 20 mM phosphate buffer (pH 7.4) containing 0.15 M NaCl.
Determination of Immunoreactive '"I-rh-Renin
Rabbit-specific anti-rh-renin antiserum was used to detect '"I-rh-renin in samples of plasma, urine, and liver and kidney extracts. This antiserum completely cross-reacted with native human kidney and plasma renin. The 50% inhibitory concentrations of this antiserum for pure native human renal renin 21 and plasma renin were 7.5 x 10* and 2 x 10 4 , respectively. Nonimmunized rabbit serum was used as the control. For plasma samples, 25 fil of plasma was added to 475 fi\ of the antiserum, diluted with 50 mM phosphate buffer (pH 7.4) containing 0.1 M NaCl and 0.3% BSA (1 :2500) and was incubated for 48 hours at 4 °C. Then, 100 fi\ of goat antirabbit Immunoglobulin G antiserum diluted with the same buffer (1:200) was added and the preparation further incubated for 24 hours at 4 °C, followed by centrifugation at 3000 rpm for 20 minutes at 4 °C, for the separation of antibody-bound and free radioactivities. Both precipitate and supernatant were counted for I25 I and I31 I radioactivities. For liver extract and urine and for kidney extract, 25-and 15-fil aliquots, respectively, were incubated with specific antiserum or nonimmunized serum, as described. After incubation for 24 hours at 4 °C, 100 fi\ of 1.6% rabbit -y-globulin (final concentration, 0.1%) and 1 ml of 20% polyethylene glycol 6000 (final concentration, 12.5%) were added to the incubation mixture, followed by centrifugation at 3000 rpm for 15 minutes at 4 °C, and the radioactivity in both supernatant and precipitate was measured. In all assays, the 123 I radioactivity precipitable with specific antiserum was corrected for that seen with nonimmunized rabbit serum. Nonspecific binding with nonimmunized rabbit serum was only 2 to 5% throughout the assays. Thus, l23 I-rh-renin in each sample could be specifically measured using this immunoprecipitation method. I-labeled human serum albumin for the determination of plasma volume, in 500 /il of phosphate-buffered saline (PBS) containing 0.3% BSA. The tubes were then flushed with 500 jil of saline. Then, 5, 10, 15, 20, 30, 60, 90, and 120 minutes after the injection, 300 /il of arterial blood was collected from the cannulated femoral artery into chilled tubes containing Na 2 -EDTA powder, and the volume of blood withdrawn was replaced each time with the same volume of heparinized saline (20 U/ml). Immediately after blood sampling at 120 minutes, the animals were killed by a bolus injection of pentobarbital and organ distributions of 125 I-rh-renin at 120 minutes were studied. The plasma was separated from the whole blood by centrifugation at 3000 rpm for 20 minutes at 4 °C. An aliquot of 25 ^1 of each plasma sample was used for the determination of immunoreactive 125 I-rhrenin, as described. For each animal, the radioactivity of immunoreactive 12i I-rh-renin in the plasma was plotted semilogarithmically against time. Plasma disappearance curves of immunoreactive l25 I-rhrenin were analyzed according to a two-compartment exponential model, as reported. 6 Lines of best fit were determined by the nonlinear least-squares method.
Organ Distribution of I25 I-rh-Renin in Marmosets
Organ distribution of 125 I-rh-renin was studied 30 and 120 minutes after the intravenous injection of l25 I-rh-renin (7.7-9.0 x 10 6 cpm) and 131 I-labeled human serum albumin (2.0 x 10 3 cpm). Immediately after the blood sampling at 30 or 120 minutes, the animals were killed by a bolus injection of pentobarbital. The urine in the bladder was collected with a syringe, and heart, lung, liver, kidneys, adrenal glands, testes or ovaries, and spleen were removed. Each organ was rinsed with cold saline, weighed, and counted for I23 I and I31 I radioactivities.
Liver and kidneys were homogenized with cold phosphate buffer (pH 7.4) using a glass homogenizer (1:10, wt/vol). I-rh-renin was not catabolized when incubated with liver or kidney homogenates at pH 7.4 for 3 hours at 37 °C or for 72 hours at 4 °C. The supernatant was separated from the whole homogenate by centrifugation at 105,000 g for 60 minutes at 4 °C.
The level of I3I I radioactivity in an organ was assumed to reflect contamination with blood of the injected albumin. With The labeled renin (2 x 10 3 cpm) was incubated with 1 ml of monkey or human plasma for 1, 3, or 7 hours at 37 °C. The incubated sample (500 /il) was applied to a G 3000 SW column at a flow rate of 0.5 ml/min at room temperature, with fractions of 0.5 ml being collected. Total radioactivity and radioactivity precipitable with specific antirenin antibody in each fraction were counted.
Molecular Weight Determination
The molecular weight of radioactive substances in plasma, liver and kidney extracts, and urine was measured by HPLC on a G 3000 SW column equilibrated with PBS at a flow rate of 0.5 ml/min at room temperature. 6 u Fractions of 0.5 ml were collected. The 125 I-rh-renin in each fraction was measured using the immunoprecipitation technique described.
Measurement of Radioactivity

I and
131
I radioactivities were assayed with a two-channel y-counter (Packard Model Auto Gamma 500 C Counting System, Rockville, MD, USA). Corrections were made for isotope spillover, decay, and counting efficiency. Spillover of I31 I into the I channel was 15%. There was no spillover of 
Results
Pressor Activity of Recombinant Human Renin
As shown in Figure 1 , the intravenous administration of rh-renin (1 ^g/kg) to an anesthetized cynomolgus monkey resulted in a 31 ± 5 mm Hg rise in mean blood pressure, in association with an increase in plasma angiotensins I and II from 39.0 ± 12.8 to 1549.0 ± 686.6 pg/ml and from 8.2 ± 1.2 to 283.6 ± 98.5 pg/ml, respectively (mean ± SE; n = 3). Pretreatment with captopril (1 mg/kg i.v.) completely blocked the pressor effect. Thus, rhrenin showed pressor activity by cleaving angiotensin I from circulating monkey angiotensinogen, a finding in agreement with the data on native human renin.
23
Iodination of Recombinant Human Renin
As shown in Figure 2A , most of the 125 I-rh-renin applied was adsorbed to a concanavalin A column and eluted with 50 mM a-methyl-D-mannoside, thereby indicating the glycosylation of this rh-renin. Rechromatography of this purified 125 I-rh-renin on a G 3000 SW column showed a single symmetrical peak with a retention time of 39.0 minutes, corresponding to a molecular weight of 42,000 ( Figure  2B ).
125
I-rh-renin retained the immunoreactivity and pressor activity, thereby indicating little iodination damage.
I-rh-renin was stored in PBS containing 0.5% BSA at 4 °C and used within 1 week after iodination, during which time the immunoreactivity and pressor activity remained unchanged. In addition, BSA did not bind to this labeled renin.
Plasma Disappearance of '"i-rh-Renin
As shown in Figure 3 , the disappearance of immunoreactive 125 I-rh-renin from the circulation could be resolved into two exponential components, the half-life for the rapid phase and for the slow phase being 12.1 ± 1.9 and 120.3 ± 16.4 minutes (means ± SE), respectively, and the metabolic clearance rate being 1.17 ± 0.26 ml/min/kg (n = 6).
The HPLC profile of the plasma, as shown in I-rh-renin decreased while the degradation products with a low molecular weight increased.
In Vitro Incubation of l25 I-rh-Renin with Plasma
As shown by the HPLC profile in Figure 5 , incubation of 123 I-rh-renin with monkey plasma for 3 hours at 37 °C resulted in no degradation of the labeled renin and no loss of its immunoreactivity. Similar results were observed during the incubation with human plasma.
Organ Distribution of lu I-rh-Renln
As shown in Table 1 , thirty minutes after the injection, 43.1 ± 0.9 and 3.5 ± 0.5% of the injected dose accumulated in the liver and kidney, respectively, and 52.3 ± 2.6 and 45.4 ± 4.0%, respectively, of the accumulated radioactivities were immunoreactive examined, except for the spleen, less than 1% of the total administered dose was recovered at 30 minutes. At 120 minutes, the accumulated dose in the liver and kidney decreased to 13.1 ± 3.8 and 3.0 ± 0.4%, respectively, and the percentage of immunoreactive 125 I-renin in relation to total 123 I decreased to 26.1 ± 6.4 and 30.7 ± 3.2%, respectively (n = 6).
The accumulated radioactivities per gram of tissue weight at 30 minutes were 405 ± 79 and 163 ± 29 x 1$ cpm/g tissue for the liver and kidney and, at 120 minutes, were 101 ± 36 and 137 ± 17 x 10 3 cpm/g tissue for the liver and kidney, respectively. Thus, the amount of accumulated gram of tissue was similar between the liver and kidney.
Cumulative excretion of 125 I-rh-renin into the urine up to 120 minutes was less than 2% of the injected dose (n = 3), thereby indicating the negligible urinary excretion of renin, a finding consistent with the data in the dog 24 and rat. 6 HPLC profiles of liver and kidney extracts at 30 and 120 minutes showed two major peaks, including immunoreactive l23 I-rh-renin and the degradation products with a low molecular weight (Figure 6 ). At 120 minutes, the 123 I-rh-renin peak decreased and was accompanied by an increase in the degradation products.
Discussion rh-Renin was prepared by trypsin activation of prorenin synthesized by Chinese hamster ovary cells. The rh-renin 14 ' 1S has physicochemical characteristics similar to those of native human renal renin, 17 including compositional or N-terminal amino acid sequence, molecular weight, isoelectric point, specific enzymatic activity, and optimum pH against hog angiotensinogen. In addition, as shown in Figure 1 , rh-renin had as potent a pressor activity as the native human renin has. 23 In the present study, we used as a probe highly purified rh-renin labled with 123 I and specific antiserum. Clearance of exogenously administered rh-renin was studied in the monkey, a species with characteristics of the reninangiotensin system similar to those in humans. This seems to be a useful model for studying the human renin-angiotensin system. 25 In studies of the clearance of circulating renin, 26 -28 renin was detected in the form of its enzymatic activity. Hence, renin activity is not specific for renin itself 29 ; it is affected by various factors in the plasma 30 -3I ; and, therefore, is probably an inadequate method for evaluating the clearance of this enzyme.
Plasma disappearance of exogenously administered rh-renin in monkeys showed two exponential components, in agreement with data on the disap- pearance of renin activity from the blood circulation of humans after bilateral nephrectomy. 26 -M However, the half-life for the slow phase in the present experiments was more rapid than that reported by Michelakis and Mizukoshi 28 (120 vs 280 minutes). In their study, 28 the release of extrarenal renin into the circulation presumably led to a slower half-life, compared with findings in the present work. This labeled renin was distributed mainly in the liver, and to some extent in the kidney. As shown by the HPLC profile of the liver and kidney extracts in Figure 6 , the degradation products as well as immunoreactive 123 I-rh-renin were apparent at 30 minutes, and at 120 minutes the degradation products increased in association with a decrease in l25 I-rh-renin. In vitro incubation of l25 I-rh-renin with monkey (see Figure  5 ) or human plasma at 37 °C showed that the labeled renin in the plasma was not degraded. Thus, 125 I-rhrenin was taken up by the liver and kidney and was subsequently catabolized in these organs, with the resulting breakdown products returning to the circulation.
The present results are consistent with our findings that glycosylated rat renal renin given exogenously to rats is cleared from the circulation mainly by the liver. 6 -9 On the other hand, nonglycosylated mouse submaxillary renin given to mice was not distributed in the liver.
2 -5 The present study therefore confirms the importance of glycosylation of renal renin for hepatic distribution.
Investigations of the clearance of glycoproteins showed that liver cells, including hepatocytes, Kupffer's cells, and endothelial cells, possess various receptors that specifically recognize the carbohydrates of glycoproteins and participate in the uptake of glycoproteins. 32 ' M In rats, hepatocytes possess receptors specific for galactose-terminated glycoproteins, 32 while Kupffer's cells and endothelial cells have receptors specific for mannose or Nacetylglucosamine-terminated glycoproteins. 32 ' 33 The rate of uptake of glycoproteins by these liver cells and their subsequent intracellular processing depend on the carbohydrate structure. 34 In the present study, the binding of rh-renin to concanavalin A indicates glycosylation of this rh-renin, a finding consistent with the data on native renal renin of various species, including that of humans, hogs, and rats. 35 However, cells of different animal species and different types of cells glycosylate proteins in a different manner. 36 It is highly likely that the carbohydrate structure of rh-renin differs from that of native human renin; therefore, the clearance of rh-renin may differ from that of native renin. In addition, a significant difference between rh-renin and rat renin 6 in metabolic clearance rate (1.17 vs 11.4 ml/min/kg) may be partly due to differences in the carbohydrate structures.
In the present study,
125
I-rh-renin was distributed in the kidney to a small extent and was subsequently catabolized in this organ. Light and electron microscopic autoradiography of exogenously administered 125 I-labeled rat renal renin demonstrated that this renin is filtered through glomerular capillaries, reabsorbed by cells in the proximal tubules, and thereafter is distributed in the lysosomes to be degraded. 9 Immunohistochemical findings with specific human renin antiserum showed localization of renin in the proximal tubules of the human kidney. 37 Thus, some of the circulating human renin may be filtered through glomerular capillaries and reabsorbed by the proximal tubule.
In conclusion, human renin was cleared mainly by the liver, and glycosylation probably contributed to the hepatic clearance.
